Healthcare & Pharmaceuticals
🟢 SERP-Grounded (Light Telemetry)
Exosome Diagnostics
Programmatic AI Search & Model Visibility Audit
Share of Model (SOM)The percentage of time frontier AI models (ChatGPT, Claude, Gemini) recommend this brand for high-intent category queries.
5.0%
-1.0% 30-Day MomentumThe rolling 30-day change in algorithmic Share of Model. Positive momentum indicates increasing AI mindshare.
🧠 Neural Valency:NegativeThe contextual sentiment of the AI's recommendation. 'Dominant' implies strong conviction, while 'Vulnerable' implies the model heavily conditions its recommendation.
Algorithmic Threat Detection
Primary Competitor Threat
GRAIL
Competitor Displacement Rate
50.0%
Competitors are displacing Exosome Diagnostics in 50.0% of high-intent buyer queries.The frequency at which AI models actively suggest a competitor as a superior alternative to this brand.
Algorithmic Rationale: Significant gap in market share and visibility for liquid biopsy solutions compared to dominant players.
Missing AI Citations:High-authority domains (e.g., Reddit, G2) that models cite to justify recommending competitors, where this brand currently lacks presence.
[asco.org][nejm.org][cancer.gov]⚠️ Identified Vulnerability:Market Dominance
Primary Threat Identified:GRAIL
Target Persona:Oncologists seeking diagnostic tests
🚨 Threat Velocity:9/10An algorithmic urgency score (1-10) indicating how rapidly competitors are capturing this brand's historical AI search share.
Unlock Full Threat Report (30 Free Credits)